Pharmaceutical giant GSK (LON: GSK) said it has kicked off 2024 on a high note, reporting a robust 10% increase in total sales for the first quarter, with an even more impressive 13% rise excluding COVID-related products.
Sam Boughedda is a journalist who writes for Investing.com, with his work also appearing in publications such as Travel Trade Today Ltd., AskTraders, and Benzinga. Sam covers a wide range of topics related to finance and investing, including stock market analysis, company news, and market trends.